Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

Trial Profile

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CoBRIM-B
  • Most Recent Events

    • 04 Apr 2016 According to ClinicalTrials.gov status changed from recruiting to discontinued due to slow accrual.
    • 23 Jun 2015 Status changed from not yet recruiting to recruiting, according to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top